8-K: FOXO Technologies Inc. Faces NYSE Non-Compliance Notice Due to Unpaid Listing Fees

FOXO Technologies Inc. has received a notice of non-compliance from the NYSE American due to overdue listing fees, putting its continued listing status at risk.

Summary

• FOXO Technologies Inc. received a notice from the NYSE American stating they are not in compliance with continued listing standards due to unpaid listing fees that are over 180 days old.
• The company failed to pay the fees by the June 7, 2024 deadline set by the NYSE.
• This non-compliance is a result of a short-term capital allocation strategy, according to the interim CEO.
• FOXO has contacted the NYSE and plans to submit a compliance plan, highlighting recent planned acquisitions that they believe will generate significant cash flow.
• The company is now subject to procedures outlined in Section 1009 of the Company Guide.
• FOXO must submit a written response by June 17, 2024, detailing how they will pay the outstanding fees within 30 days.
• Failure to submit an acceptable plan or make progress towards full payment could lead to delisting proceedings.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the non-compliance notice and the risk of delisting. While the company expresses intent to regain compliance, the situation is concerning for investors.

Positives

• FOXO has contacted the NYSE and intends to present a compliance plan.
• The company believes recent planned acquisitions will generate meaningful cash flow, aiding in regaining compliance.
• FOXO is committed to regaining compliance with NYSE American continued listing standards.

Negatives

• FOXO is currently not in compliance with NYSE American continued listing standards.
• The non-compliance is due to an outstanding balance of listing fees over 180 days old.
• The company failed to meet the payment deadline of June 7, 2024.
• There is no assurance that the company will regain compliance with all applicable NYSE American listing standards.

Risks

• The NYSE may not accept FOXO's compliance plan.
• FOXO may be unable to satisfy other continued listing requirements.
• The company faces risks related to competition, regulatory changes, and the ability to obtain financing.
• FOXO has a history of losses and may not achieve or maintain profitability.
• There is a risk of potential delisting from the NYSE American if the company fails to comply with the requirements.

Future Outlook

FOXO intends to regain compliance with NYSE American continued listing standards, but there is no assurance that they will be successful. The company plans to submit a compliance plan to the NYSE, highlighting recent planned acquisitions that they believe will generate significant cash flow.

Management Comments

• Mark White, Interim CEO of FOXO, said, 'We regret the delinquency, which was due to short-term capital allocation strategies.'
• Mark White also stated, 'However, we have contacted NYSE and look forward to presenting our compliance plan in light of recent developments, including our recently announced planned acquisitions, which we believe would generate meaningful cashflow for the combined companies.'

Industry Context

This announcement highlights the challenges faced by biotechnology companies, particularly those with a history of losses, in maintaining compliance with exchange listing requirements. It also underscores the importance of effective capital allocation and financial management in the biotech sector.

Comparison to Industry Standards

• Many biotech companies, especially those in early stages, face challenges in maintaining profitability and meeting listing requirements.
• Companies like Novavax and Cassava Sciences have faced similar scrutiny regarding their financial health and compliance with listing standards.
• The need to raise capital and manage cash flow is a common theme in the biotech industry, and FOXO's situation is not unique.
• The ability to demonstrate a clear path to profitability and sustainable cash flow is crucial for maintaining a listing on major exchanges.

Stakeholder Impact

• Shareholders face the risk of potential delisting and a decrease in share value.
• Employees may experience uncertainty due to the company's financial challenges.
• Customers and suppliers may be concerned about the company's long-term viability.

Next Steps

• FOXO must submit a written response to the NYSE by June 17, 2024.
• The company needs to present a compliance plan to the NYSE.
• FOXO must make progress towards full payment of all past-due fees.

Key Dates

Keywords

NYSE American, non-compliance, listing fees, delisting, compliance plan, FOXO Technologies, biotechnology, acquisitions, cash flow